- Bladder cancer
Ronac Mamtani, MD, MSCE
About me
- Section Chief, Genitourinary Cancers, Hematology-Oncology
- David J. Vaughn MD Associate Professor in GU Oncology
My education and training
- Medical School: SUNY Stony Brook School of Medicine
- Residency: NewYork-Presbyterian/Weill Cornell Medical Center
- Fellowship: University of Pennsylvania Health System
Spoken languages
Reviews
239 reviews
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Insurance accepted
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Americhealth Caritas of PA VIP - LGH Only
- Amerihealth Caritas (Transplant patients only)
- Amerihealth Caritas of PA - LGH Only
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Qualifications and experience
- Medical Oncology, 2012
- International Society for Pharmacoepidemiology, International
- National Comprehensive Cancer Network (NCCN) Foundation Young Investigator Award, Grant reviewer; Oncology Clinical Practice Guidelines Committee on Bladder Cancer (Member) 2021-2024, National
- Scientific Advisory Board, Bladder Cancer Advocacy Network, National
- Scientific Program Committee for Health Services Research, American Society of Clinical Oncology; (2023-present) Scientific Program Committee Genitourinary Cancer, American Society of Clinical Oncology, Chair (2023-2024), National
- Scientific Review Committee, The U.K. Health Improvement Network, International
- Penn Genitourinary and Urologic Cancer Program
Treatments and conditions
Research
Publications
Mayer M, Seewald N, Babcock A, Homet Moreno B, Ramamurthy C, Li H, Mamtani R. Untreated advanced urothelial carcinoma (aUC) in the modern treatment era: Patterns of care from a decade-long national cohort. , 2026 American Society of Clinical Oncology Annual Meeting, Chicago IL., 44: 2026
Subramanian P, Shyamsunder S, Eshaghi K, Mamtani R, Litt HK. Gaps in patient-facing information on artificial intelligence in cancer care: A cross-sectional analysis. , 2026 American Society of Clinical Oncology Annual Meeting, Chicago IL., 44: 2026
Martei YM, Chen K, Obasohan M, Mamtani R, Aakhus E, Shulman LN, Hubbard RA, Clark A. Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer , JNCI Cancer Spectr, 10(3): 2026,pkag043
Chow RD, Rothen J, Long JB, Soulos PR, Wang X, Mamtani R, Ma S, Kunst N, Dinan MA, Gross CP. Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer , JAMA Netw Open, 9: 2026,e2614919
Litt H, Mehta P, Sahni A, Mamtani R. FDA-authorized oncology artificial intelligence and machine learning devices and their clinical evidence: A cross-sectional analysis , J Cancer Policy, 48: 2026,100743
Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Narayan V, Mei L, Takvorian S, Haas NB, Parikh RB, Mistry R, Mamtani R. OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care , Oncologist: 2026
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA. Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes , Stat Med, 45: 2026
Galsky MD, Izadmehr S, Yu M, Curtis SD, Douville C, Popoli M, Ptak J, Dobbyn L, Silliman N, Chan KG, Dorff TB, Cetnar JP, O'Neil B, D'Souza A, Mamtani R, Kyriakopoulos CE, Brody R, Sadimin E, Mehrazin R, Chowell D, Sfakianos J, Daneshmand S, Pal SK, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B, Wang Y. Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer , Proc Natl Acad Sci U S A, 123: 2026,e2533449123
Squires P, Cook EE, Song Y, Wang CY, Zhang A, Seshasayee SM, Rogiers A, Li H, Mamtani R Treatment Patterns, Disease Recurrence, and Overall Survival in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: A Population-Level Claims-Based Analysis , Clin Genitourin Cancer, 24(1): 2026,102466
Wang X, Long JB, Rothen J, Huang S, Soulos PR, Goldberg SB, Robinson TJ, Ma S, Mamtani R, Presley CJ, Wang SY, Kunst N, Gross CP, Dinan MA. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling , J Natl Compr Canc Netw, 24: 2026,e257131